AnaptysBio. Every tracked FinTwit mention of $ANAB, newest first. 12 mentions since the first on Nov 21, 2025. See the price chart.
November 2025 · 12 mentions
Nov 27
Jacob Plieth — Seems my story on $GSK $ANAB falling out was correct in speculating that trials of B7-H3 ADC combos were a problem. Surprisingly, the complaint also cites the I-Spy trial - curious…↗
Nov 21
Jacob Plieth — Some background: when researching this story I tried numerous times to call the contact cited at the bottom of $GSK's PR - no reply.
I also emailed $ANAB for comment; they replied…↗
Nov 21
Jacob Plieth — Here's why $GSK and $ANAB have fallen out (again), and what's at stake. Via @ApexOnco -> https://t.co/5few1aPJag https://t.co/tbURMQvCOm↗
Nov 21
Jacob Plieth — @Lord_of_Biotech @Loving_pharma To which $ANAB will claim that the 2020 $GSK settlement related only to combos of Zejula https://t.co/6mJ9GftPYq↗
Nov 21
Jacob Plieth — @Lord_of_Biotech @Loving_pharma One possibility: $GSK thought that the 2020 settlement allowed it to study Keytruda combos. $ANAB↗
Nov 21
Jacob Plieth — @Loving_pharma @Lord_of_Biotech ...and remember the last time $ANAB alleged this $GSK ended up paying it $60m and >doubling the Jemperli royalty payable!↗
Nov 21
Jacob Plieth — @Loving_pharma @Lord_of_Biotech So the mere allegation by $ANAB that $GSK studying Keytruda was in breach of the deal put $ANAB itself in material breach? Extraordinary.↗
Nov 21
Jacob Plieth — @Lord_of_Biotech If the 2020 settlement relating to Zejula combos is anything to go by, then yes. Still unclear what "material breach" $GSK is accusing $ANAB of having committed th…↗
Nov 21
Jacob Plieth — More detail just out from $ANAB. Seems to be a repeat of the allegations vs $GSK re Zejula, which resulted in Anaptys getting an increased royalty rate in 2020 https://t.co/qExYywg…↗
Nov 21
Jacob Plieth — Reminder of the terms of the $ANAB $GSK deal https://t.co/249IraFiyy↗
Nov 21
Jacob Plieth — Some possibly relevant detail from $ANAB re the $GSK deal https://t.co/8oDw03ijFt↗
Nov 21
Jacob Plieth — Spectacular falling out between $GSK & $ANAB. Is this the end of the Jemperli deal? https://t.co/jZV3zDgEW8↗